



ANDA 202388

**ANDA APPROVAL**

Sandoz Inc.  
Attention: Gregory Seitz  
Head U.S. Regulatory Affairs Generics

Dear Gregory Seitz:

This letter is in reference to your abbreviated new drug application (ANDA) received for review on October 18, 2010, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Sitagliptin and Metformin Hydrochloride Tablets, 50 mg/500 mg and 50 mg/1,000 mg.

Reference is also made to the tentative approval letter issued by this office on July 30, 2013, the complete response letter issued by this office on January 23, 2025, and to any amendments thereafter.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug meets the requirements for approval under the FD&C Act. Accordingly, the ANDA is **approved**, effective on the date of this letter. We have determined your Sitagliptin and Metformin Hydrochloride Tablets, 50 mg/500 mg and 50 mg/1,000 mg, to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Janumet Tablets, 50 mg/500 mg and 50 mg/1,000 mg, of Merck Sharp & Dohme LLC (Merck) NDA - 022044.

The RLD upon which you have based your ANDA, Merck's Janumet Tablets, 50 mg/500 mg and 50 mg/1,000 mg, is subject to periods of patent protection. The following patents and expiration dates (with pediatric exclusivity added) are currently listed in the Agency's publication titled *Approved Drug Products with Therapeutic Equivalence Evaluations* (the "Orange Book"):

<u>U.S. Patent Number</u>	<u>Expiration Date</u>
7,326,708 (the '708 patent)	May 24, 2027
8,414,921 (the '921 patent)	January 21, 2029

Your ANDA contains paragraph IV certifications to each of the patents under section 505(j)(2)(A)(vii)(IV) of the FD&C Act stating that the patents are invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Sitagliptin and Metformin Hydrochloride Tablets, 50 mg/500 mg and 50 mg/1,000 mg, under this ANDA. You

have notified the Agency that Sandoz Inc. (Sandoz) complied with the requirements of section 505(j)(2)(B) of the FD&C Act and that no action for infringement of the '708 patent) was brought against Sandoz within the statutory 45-day period.

With respect to 180-day generic drug exclusivity, we note that Sandoz was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Sitagliptin and Metformin Hydrochloride Tablets, 50 mg/500 mg and 50 mg/1,000 mg. Therefore, with this approval, Sandoz is eligible for 180 days of shared generic drug exclusivity for Sitagliptin and Metformin Hydrochloride Tablets, 50 mg/500 mg and 50 mg/1,000 mg. FDA notes that after issuance of this approval letter, eligibility for 180-day exclusivity is subject to future events that may result in forfeiture of exclusivity under section 505(j)(5)(D) of the FD&C Act. This exclusivity, which is provided for under section 505(j)(5)(B)(iv) of the FD&C Act, begins to run from the date of the commercial marketing identified in section 505(j)(5)(B)(iv). Please submit correspondence to this ANDA notifying the Agency within 30 days of the date of the first commercial marketing of this drug product or the RLD. If you do not notify the Agency within 30 days, the date of first commercial marketing will be deemed to be the date of the drug product's approval. See 21 CFR 314.107(c)(2).

Please note that if FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for a listed drug, an ANDA referencing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

### **COMPENDIAL STANDARDS**

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standard for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP's website as <https://www.uspnf.com/>.

**REQUIREMENTS AND RECOMMENDATIONS POST APPROVAL**

Under applicable statutes, regulations, and guidances, your ANDA may be subject to certain requirements and recommendations post approval, including requirements regarding changes to approved ANDAs, postmarketing reporting, promotional materials, and annual facility fees, among others. For information on post-approval requirements and recommendations for ANDAs and a list of resources for ANDA holders, we refer you to <https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/requirements-and-resources-approved-andas>.

Sincerely yours,

*{See appended electronic signature page}*

For Kendra S. Stewart, R.Ph., Pharm.D.  
CAPT, United States Public Health Service  
Director  
Office of Regulatory Operations  
Office of Generic Drugs  
Center for Drug Evaluation and Research



Paul  
Levine

Digitally signed by Paul Levine

Date: 12/02/2025 02:29:06PM

GUID: 56323ddc003554a87fad6698c2baa467